FertilAI develops the Fertilane AI platform that integrates with clinic electronic medical records (EMRs) to improve predictability, clinical outcomes, and the patient experience throughout the fertility journey. The platform supports identifying optimal embryo transfer timing, optimizing decision-making during stimulation cycles, ovulation tracking, timed intercourse support, and facilitating intrauterine insemination (IUI). FertilAI also offers a mobile patient app to improve two-way communication between clinics and patients. The company is led by CEO Rohi Hourvitz and is based in Tel Aviv, Israel. In 2024 the product was used globally by more than 50 physicians across 20,000+ patients. The company intends to use new funding to expand its market presence, hire personnel, and reinforce R&D efforts.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2024